A pivotal trial funded by the National Institutes of Health found that an artificial pancreas system from Tandem Diabetes Care (NSDQ:TNDM) was more effective than existing treatments for people with Type 1 diabetes.
The Tandem system combines its t:slim X2 insulin pump and Control-IQ advanced hybrid closed-loop technology with a continuous glucose monitor made by DXCM, the recently approved G6 CGM. Control-IQ is designed to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly. Results from the study, which was funded by NIH’s National Institute of Diabetes & Digestive & Kidney Diseases, were published in the New England Journal of Medicine.
Get the full story at our sister site, Drug Delivery Business News.
